Home  »  Business   »  There Has Been A -1.66% Decline For PTC Therapeuti...

There Has Been A -1.66% Decline For PTC Therapeutics Inc. (NASDAQ: PTCT). So What’s Next?

PTC Therapeutics Inc. (NASDAQ:PTCT)’s traded shares stood at 1.47 million during the last session, with the company’s beta value hitting 0.40. At the close of trading, the stock’s price was $47.30, to imply a decrease of -1.66% or -$0.8 in intraday trading. The PTCT share’s 52-week high remains $55.58, putting it -17.51% down since that peak but still an impressive 47.12% since price per share fell to its 52-week low of $25.01. The company has a valuation of $3.63B, with an average of 0.87 million shares in intraday trading volume over the past 10 days and average of 700.17K shares over the past 3 months.

Analysts have given a consensus recommendation of an Overweight for PTC Therapeutics Inc. (PTCT), translating to a mean rating of 2.50. Of 16 analyst(s) looking at the stock, 1 analyst(s) give PTCT a Sell rating. 1 of those analysts rate the stock as Overweight while 7 advise Hold as 6 recommend it as a Buy. 1 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$1.59.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


PTC Therapeutics Inc. (NASDAQ:PTCT) trade information

After registering a -1.66% downside in the last session, PTC Therapeutics Inc. (PTCT) has traded red over the past five days. The stock hit a weekly high of 48.33 this Friday, 03/17/23, dropping -1.66% in its intraday price action. The 5-day price performance for the stock is 6.94%, and 2.51% over 30 days. With these gigs, the year-to-date price performance is 23.92%. Short interest in PTC Therapeutics Inc. (NASDAQ:PTCT) saw shorts transact 5.8 million shares and set a 6.59 days time to cover.

Analysts on Wall Street suggest a consensus price target of $51.53, implying an increase of 8.21% to the stock’s current value. The extremes give us $35.00 and $75.00 for target low and target high price respectively. As such, PTCT has been trading -58.56% off suggested target high and 26.0% from its likely low.

PTC Therapeutics Inc. (PTCT) estimates and forecasts

Looking at statistics comparing PTC Therapeutics Inc. share performance against respective industry, we note that the company has outperformed competitors. PTC Therapeutics Inc. (PTCT) shares are -11.84% down over the last 6 months, with its year-to-date growth rate higher than industry average at 41.46% against 10.80%. Revenue is forecast to grow 21.70% this quarter before jumping 27.00% for the next one. The rating firms project that company’s revenue will grow 33.10% compared to the previous financial year.

Revenue forecast for the current quarter as set by 12 analysts is $189.14 million. Meanwhile, for the quarter ending Mar 2023, a total of 7 analyst(s) estimate revenue growth to $213.5 million.Earnings reports from the last fiscal year show that sales brought in $165.23 million and $148.74 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 14.50% before jumping 43.50% in the following quarter.

An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -31.10% for the past 5-year period. While 2023 is set for a -4.80% return in earnings, projections for the next 5 years are at -9.51% annually.

PTCT Dividends

PTC Therapeutics Inc. has its next earnings report out between May 01 and May 05. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. PTC Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.

PTC Therapeutics Inc. (NASDAQ:PTCT)’s Major holders

PTC Therapeutics Inc. insiders hold 2.71% of total outstanding shares, with institutional holders owning 105.95% of the shares at 108.90% float percentage. In total, 105.95% institutions holds shares in the company, led by FMR, LLC. As of Sep 29, 2022, the company held over 10.73 million shares (or 14.70% of shares), all amounting to roughly $538.7 million.

The next major institution holding the largest number of shares is Wellington Management Group, LLP with 7.49 million shares, or about 10.26% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $376.05 million.

We also have Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the PTC Therapeutics Inc. (PTCT) shares. Going by data provided on Nov 29, 2022, Fidelity Select Portfolios – Biotechnology holds roughly 2.27 million shares. This is just over 3.11% of the total shares, with a market valuation of $94.1 million. Data from the same date shows that the other fund manager holds a little less at 2.14 million, or 2.93% of the shares, all valued at about 107.21 million.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts